Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy and/or radiotherapy

Enzalutamide is currently in clinical development for the treatment of high-risk non-metastatic prostate cancer (cancer that has not spread beyond the prostate) that has been previously treated with a radical prostatectomy (surgery to remove the prostate gland) and/or radiotherapy. Prostate cancer develops in the prostate gland and is the most common cancer in men in the UK. The symptoms may vary depending on the stage of cancer but can include pain, tiredness, and problems emptying the bladder and the bowels. There are currently limited non-hormonal treatment options available for patients with non-metastatic prostate cancer that has progressed after standard care treatment, therefore more effective treatments are needed.